Edwards Lifesciences Gets Big Boost as CMS Expands TAVR Coverage to Asymptomatic Patients
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
/ 77 items
#XY Analyst Up/Down↓
PepGen Shares Trading Below Cash as Craig-Hallum Starts Coverage with Buy Rating
PepGen has Buy ratings; DM1 drug data mixed, big 2026 results could drive huge upside from very low stock price.
JPMorgan Sees 127% Upside in Camp4 Therapeutics as It Upgrades to Overweight on CMP-002 Potential
JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
Twist Bioscience Stock Surges Toward $1 Billion Goal as Canaccord Joins Bullish Chorus
Canaccord is bullish on Twist Bioscience, citing AI-driven DNA tech growth, strong revenue gains, and upside to $90 target.